Pfizer Inc’s new CEO on Tuesday outlined plans to reduce the company’s spending and work force and focus more sharply on promising drugs as it faces slowing sales of some of its blockbuster medicines.
In the latest quarter, a tax benefit and rising sales from products gained in its Wyeth acquisition helped Pfizer just beat Wall Street expectations. Profits nearly quadrupled, compared with a 2009 quarter hurt by big restructuring charges, but overall sales are slowing and the company said its revenue will drop next year.
Still, shares rose more than 5 percent on Tuesday as chief executive Ian Read announced a US$5 billion stock buyback and an ambitious overhaul of operations that will cut jobs and research spending while aiming to boost research productivity and emerging market sales. Pfizer will cut its 110,600-person work force by up to 5 percent.
The strategy outlined by Read includes many elements being tested across the pharmaceutical industry and tried by his predecessor, Jeffrey Kindler. He was ousted by Pfizer’s board unexpectedly on Dec. 6 after four years of languishing share prices and several failures of promising drugs in late testing, including a successor to cholesterol fighter Lipitor, the world’s top-selling drug.
“A lot of what we are doing individually you can see in different companies,” Read said, citing plans to increase external collaborations and prune the research portfolio to diseases with the best medical and financial payoffs. “I think we have a holistic game plan that is functioning as a total engine” to drive productivity.
The world’s largest drugmaker by revenue, Pfizer said fourth-quarter net income was US$2.89 billion, or US$0.36 per share, up from US$767 million, or US$0.10 a share, a year ago.
Adjusted net income was down 1 percent, at US$3.77 billion, or US$0.47 per share. Numerous one-time items brought a total gain of US$0.11 per share, including a US$2 billion benefit from a tax settlement, legal costs, and a host of restructuring and other expenses from Pfizer’s US$68 billion purchase of Wyeth in October 2009.
Revenue totaled US$17.56 billion, up 6 percent, as a dip in US sales was more than offset by higher sales elsewhere. For all of last year, Pfizer reported a 4 percent decline in net income, to US$8.26 billion, or US$1.02 per share. Revenue totaled US$67.81 billion, up 36 percent, thanks to US$18.1 billion from sales of Wyeth products.
Pfizer gave its first financial forecast for this year, for earnings per share of US$2.16 to US$2.26, excluding just over US$1 in one-time items. It expects flat revenue, at about US$67 billion.
Pfizer plans to cut research spending next year by US$1.5 billion, to about US$8.25 billion. The research cuts will come mainly from phasing out work in four disease areas: allergy and respiratory, urology, general medicine and tissue repair.
Three experts in the high technology industry have said that US President Donald Trump’s pledge to impose higher tariffs on Taiwanese semiconductors is part of an effort to force Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to the negotiating table. In a speech to Republicans on Jan. 27, Trump said he intends to impose tariffs on Taiwan to bring chip production to the US. “The incentive is going to be they’re not going to want to pay a 25, 50 or even a 100 percent tax,” he said. Darson Chiu (邱達生), an economics professor at Taichung-based Tunghai University and director-general of
‘LEGACY CHIPS’: Chinese companies have dramatically increased mature chip production capacity, but the West’s drive for secure supply chains offers a lifeline for Taiwan When Powerchip Technology Corp (力晶科技) entered a deal with the eastern Chinese city of Hefei in 2015 to set up a new chip foundry, it hoped the move would help provide better access to the promising Chinese market. However, nine years later, that Chinese foundry, Nexchip Semiconductor Corp (合晶集成), has become one of its biggest rivals in the legacy chip space, leveraging steep discounts after Beijing’s localization call forced Powerchip to give up the once-lucrative business making integrated circuits for Chinese flat panels. Nexchip is among Chinese foundries quickly winning market share in the crucial US$56.3 billion industry of so-called legacy
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday held its first board of directors meeting in the US, at which it did not unveil any new US investments despite mounting tariff threats from US President Donald Trump. Trump has threatened to impose 100 percent tariffs on Taiwan-made chips, prompting market speculation that TSMC might consider boosting its chip capacity in the US or ramping up production of advanced chips such as those using a 2-nanometer technology process at its Arizona fabs ahead of schedule. Speculation also swirled that the chipmaker might consider building its own advanced packaging capacity in the US as part
A move by US President Donald Trump to slap a 25 percent tariff on all steel imports is expected to place Taiwan-made steel, which already has a 25 percent tariff, on an equal footing, the Taiwan Steel & Iron Industries Association said yesterday. Speaking with CNA, association chairman Hwang Chien-chih (黃建智) said such an equal footing is expected to boost Taiwan’s competitive edge against other countries in the US market, describing the tariffs as "positive" for Taiwanese steel exporters. On Monday, Trump signed two executive orders imposing the new metal tariffs on imported steel and aluminum with no exceptions and exemptions, effective
RSS